Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations

Published:2018-04-16 Issue:5 Volume:7 Page:309-320
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Willmann Stefan¹,Zhang Liping²,Frede Matthias¹,Kubitza Dagmar³,Mueck Wolfgang⁴,Schmidt Stephan⁵,Solms Alexander⁶,Yan Xiaoyu²,Garmann Dirk¹

Affiliation:

1. Clinical Pharmacometrics, Bayer AG; Wuppertal Germany

2. Global Clinical Pharmacology, Janssen Research and Development LLC; Raritan New Jersey USA

3. Pharmacodynamics Cardiovascular, Bayer AG; Wuppertal Germany

4. Clinical Pharmacokinetics Cardiovascular, Bayer AG; Wuppertal Germany

5. Department of Pharmaceutics; Center for Pharmacometrics and Systems Pharmacology, University of Florida; Orlando Florida USA

6. Clinical Pharmacometrics, Bayer AG; Berlin Germany

Funder

Bayer AG

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/psp4.12288/fullpdf

Reference39 articles.

1. https://www.fda.gov/downloads/Drugs/Guidances/ucm070246.pdf 2000

2. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban;Mueck;Clin. Pharmacokinet.,2014

3. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects;Kubitza;Eur. J. Clin. Pharmacol.,2005

4. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement;Eriksson;J. Thromb. Haemost.,2006

5. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement;Eriksson;Circulation,2006

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exposure Matching‐Based Pediatric Dose Selection for Drugs with Renal Excretion – Lessons Learned from Pediatric Development of Direct Oral Anticoagulants;Clinical Pharmacology & Therapeutics;2024-08-13

2. Full-dose rivaroxaban in patients with a history of bariatric surgery: bridging the knowledge gap through a phase 1 study;Journal of Thrombosis and Haemostasis;2024-07

3. Efficacy and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients (BMI ≥ 30 kg/m2) with Atrial Fibrillation or Venous Thromboembolism: An Updated Systematic Review and Meta-Analysis;Journal of Clinical Medicine;2024-06-27

4. Pharmacokinetics of single‐dose rivaroxaban under fed state in obese vs. non‐obese subjects: An open‐label controlled clinical trial (RIVOBESE‐PK);Clinical and Translational Science;2024-06

5. An extension of biorelevant fed-state dissolution tests to clinical pharmacokinetics – A study on gastrointestinal factors influencing rivaroxaban exposure and efficacy in atrial fibrillation patients;International Journal of Pharmaceutics;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3